生命科学资讯

Protego plans pivotal trial for AL amyloidosis prospect with $130M series B

Protego gets $130M for AL amyloidosis drug from leaders behind Vyndaqel

Generate:Biomedicines to start Phase 3 studies for TSLP antibody

With $130M, Protego pushes forward a new type of amyloidosis drug

Quadrant Capital Group LLC Purchases 3,395 Shares of Agilent Technologies, Inc. $A - MarketBeat

HSBC Upgrades Thermo Fisher Scientific to Buy From Hold, Adjusts Price Target to $670 From $550 - MarketScreener

Redefining CAR-T speed and strength with DAR-T™: A conversation with Nicholas Kirian

Expanding access in oncology trials: The case for a paired tissue-plasma approach

Specialty pharmacy’s secret weapon: The unsung power of the enrollment form

From feedstocks to infrastructure, Indiana’s bioeconomy is on the move

Meeting patients where they are: tailored support to drive recruitment and retention

Cytiva, Veeda Lifesciences drive biopharma innovation with new host cell protein services centre - IndiaMedToday

We Think Lonza Group (VTX:LONN) Is Taking Some Risk With Its Debt - simplywall.st

Roche: Despite Some Study Setbacks, Pipeline Gives Me Increasing Confidence (RHHBY) - Seeking Alpha

Correction: ZC3H11A mutations cause high myopia by triggering PI3K-AKT and NF-κB-mediated signaling pathway in humans and mice

Philip M. "Phil" Roche Obituary (2025) - Jamestown, NY - Lind Funeral Home, Inc. - Legacy | Obituary

10 Best Dividend Stocks Hedge Funds Are Buying - Insider Monkey

Why Lonza Group AG (LO3) stock is a must watch ticker - Market Growth Report & Capital Efficient Trade Techniques - moha.gov.vn

Agilent Technologies, Inc. $A Shares Purchased by Vinva Investment Management Ltd - MarketBeat

Agilent Technologies (A): Assessing Valuation Following Strong Q4 Results and Upbeat 2026 Guidance - simplywall.st